{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:34:40Z","timestamp":1790645680106,"version":"4.1.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.8348","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T11:01:23Z","timestamp":1621335683000},"page":"e218348","source":"Crossref","is-referenced-by-count":84,"title":["Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials"],"prefix":"10.1001","volume":"4","author":[{"given":"Karen","family":"Allison","sequence":"first","affiliation":[{"name":"New York Ophthalmology Associates, Manhattan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepkumar G.","family":"Patel","sequence":"additional","affiliation":[{"name":"New York Ophthalmology Associates, Manhattan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Greene","sequence":"additional","affiliation":[{"name":"School of Health Sciences and Practice & Institute of Public Health, New York Medical College, Valhalla"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"issue":"11","key":"zoi210263r1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"zoi210263r3","first-page":"887","article-title":"Glaucoma is second leading cause of blindness globally.","volume":"82","author":"Kingman","year":"2004","journal-title":"Bull World Health Organ"},{"issue":"4","key":"zoi210263r4","first-page":"450","article-title":"Primary open-angle glaucoma in individuals of African descent: a review of risk factors.","volume":"6","author":"Salowe","year":"2015","journal-title":"J Clin Exp Ophthalmol"},{"issue":"4","key":"zoi210263r5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States.","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"zoi210263r6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1001\/archopht.124.11.1625","article-title":"The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study.","volume":"124","author":"Friedman","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"zoi210263r7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/archopht.118.6.819","article-title":"Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study.","volume":"118","author":"Mu\u00f1oz","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"zoi210263r8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.1991.03470030069026","article-title":"Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey.","volume":"266","author":"Tielsch","year":"1991","journal-title":"JAMA"},{"issue":"4","key":"zoi210263r12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40142-017-0131-8","article-title":"Primary open-angle glaucoma genetics in African Americans.","volume":"5","author":"Restrepo","year":"2017","journal-title":"Curr Genet Med Rep"},{"issue":"18","key":"zoi210263r13","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review.","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"zoi210263r16","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1001\/jamaophthalmol.2013.4694","article-title":"Socioeconomic disparity in use of eye care services among US adults with age-related eye diseases: National Health Interview Survey, 2002 and 2008.","volume":"131","author":"Zhang","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"zoi210263r17","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.ajo.2011.08.045","article-title":"Vision health disparities in the United States by race\/ethnicity, education, and economic status: findings from two nationally representative surveys.","volume":"154","author":"Zhang","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"zoi210263r21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ajo.2014.04.027","article-title":"Intracameral triamcinolone acetonide in glaucoma surgery: a prospective randomized controlled trial.","volume":"158","author":"Koval","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"zoi210263r22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1471-2415-14-151","article-title":"Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.","volume":"14","author":"DuBiner","year":"2014","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"zoi210263r23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: overcoming critical barriers.","volume":"44","author":"Clark","year":"2019","journal-title":"Curr Probl Cardiol"},{"issue":"7","key":"zoi210263r24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/IJG.0b013e3181c4aeac","article-title":"Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study).","volume":"19","author":"Birt","year":"2010","journal-title":"J Glaucoma"},{"key":"zoi210263r25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/EDBK_100021","article-title":"Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy.","volume":"39","author":"Nazha","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"zoi210263r26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0092070305283778","article-title":"Nonresponse and generalizability in academic research.","volume":"34","author":"Blair","year":"2006","journal-title":"J Acad Mark Sci"},{"issue":"11","key":"zoi210263r27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jama.2021.2104","article-title":"The reporting of race and ethnicity in medical and science journals: comments invited.","volume":"325","author":"Flanagin","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"zoi210263r28","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2217\/14622416.8.9.1115","article-title":"Pharmacogenomics research involving racial classification: qualitative research findings on researchers\u2019 views, perceptions and attitudes towards socioethical responsibilities.","volume":"8","author":"Egalit\u00e9","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"7","key":"zoi210263r29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/archophthalmol.2011.163","article-title":"Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population.","volume":"129","author":"Murakami","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"zoi210263r31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030019","article-title":"Are racial and ethnic minorities less willing to participate in health research?","volume":"3","author":"Wendler","year":"2006","journal-title":"PLoS Med"},{"key":"zoi210263r2","unstructured":"Glaucoma Research Foundation. Glaucoma facts and stats. Accessed July 15, 2020. https:\/\/www.glaucoma.org\/glaucoma\/glaucoma-facts-and-stats.php"},{"key":"zoi210263r9","unstructured":"National Eye Institute. Glaucoma data and statistics. Accessed July 24, 2020. https:\/\/www.nei.nih.gov\/learn-about-eye-health\/resources-for-health-educators\/eye-health-data-and-statistics\/glaucoma-data-and-statistics"},{"key":"zoi210263r10","unstructured":"Boyd? K. What is glaucoma? Accessed July 16, 2020. https:\/\/www.aao.org\/eye-health\/diseases\/what-is-glaucoma"},{"key":"zoi210263r11","unstructured":"Mayo Clinic. Glaucoma. Accessed July 16, 2020. https:\/\/www.mayoclinic.org\/diseases-conditions\/glaucoma\/symptoms-causes\/syc-20372839"},{"key":"zoi210263r14","unstructured":"FDA. FDA\u2019s action plan for FDASIA Section 907: questions and answers. Accessed July 21, 2020. https:\/\/www.fda.gov\/regulatory-information\/food-and-drug-administration-safety-and-innovation-act-fdasia\/fdas-action-plan-fdasia-section-907-questions-and-answers"},{"key":"zoi210263r15","unstructured":"FDA. FDASIA section 907: inclusion of demographic subgroups in clinical trials. Accessed July 21, 2020. https:\/\/www.fda.gov\/regulatory-information\/food-and-drug-administration-safety-and-innovation-act-fdasia\/fdasia-section-907-inclusion-demographic-subgroups-clinical-trials"},{"key":"zoi210263r18","unstructured":"PRISMA. PRISMA statement. Accessed August 16, 2020. http:\/\/prisma-statement.org\/PRISMAStatement\/"},{"key":"zoi210263r19","unstructured":"United Nations Statistical Division. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. Accessed August 1, 2020. https:\/\/unstats.un.org\/unsd\/methodology\/m49\/"},{"key":"zoi210263r20","unstructured":"United States Census Bureau. About race. Accessed July 23, 2020. https:\/\/www.census.gov\/topics\/population\/race\/about.html#:~:text=OMB%20requires%20five%20minimum%20categories,Hawaiian%20or%20Other%20Pacific%20Islander"},{"key":"zoi210263r30","unstructured":"NORC at the University of Chicago. The economic burden of vision loss and eye disorders in the United States. Accessed July 28, 2020. https:\/\/www.norc.org\/Research\/Projects\/Pages\/the-economic-burden-of-vision-loss-and-eye-disorders-in-the-united-states.aspx"},{"key":"zoi210263r32","unstructured":"FDA. Enhancing the diversity of clinical trial populations\u2014eligibility criteria, enrollment practices, and trial designs guidance for industry. Accessed July 24, 2020. https:\/\/www.fda.gov\/media\/127712\/download"},{"key":"zoi210263r33","unstructured":"National Institutes of Health. Amendment: NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research. Accessed November 28, 2017. https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/NOT-OD-18-014.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2779939\/allison_2021_oi_210263_1620356563.84332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T11:01:35Z","timestamp":1621335695000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2779939"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.8348","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]}}}